PFG Investments LLC acquired a new position in shares of Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 141,508 shares of the company's stock, valued at approximately $566,000. PFG Investments LLC owned 1.30% of Dominari as of its most recent SEC filing.
Separately, Renaissance Technologies LLC boosted its position in shares of Dominari by 20.0% during the 4th quarter. Renaissance Technologies LLC now owns 56,326 shares of the company's stock worth $55,000 after purchasing an additional 9,400 shares in the last quarter. 42.48% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen cut Dominari from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.
Check Out Our Latest Analysis on Dominari
Dominari Stock Down 4.3%
NASDAQ:DOMH traded down $0.25 during trading hours on Wednesday, hitting $5.55. 243,301 shares of the company traded hands, compared to its average volume of 316,156. The company has a market cap of $81.25 million, a PE ratio of -1.23 and a beta of 0.57. The firm's 50-day simple moving average is $5.09 and its 200-day simple moving average is $4.35. Dominari Holdings Inc. has a one year low of $0.83 and a one year high of $13.58.
Dominari (NASDAQ:DOMH - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $0.20 earnings per share (EPS) for the quarter. The company had revenue of $6.56 million during the quarter. Dominari had a negative return on equity of 91.67% and a negative net margin of 167.73%.
Dominari Profile
(
Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Featured Articles
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
